Essa terminates an N-terminal journey
After beating "historical" Xtandi masofaniten fails to beat actual Xtandi.
Ipsen casts doubt on Pfizer’s prostate plan
Mevrometostat is the only EZH2 inhibitor in phase 3 for prostate cancer.
Pfizer makes haste to go EZ
The company sticks with EZH2, despite others adding EZH1 inhibition.
Is this the end for MacroGenics’ vobra-duo?
The company stops dosing in the troubled Tamarack trial, and is going quiet until ESMO.
Telix heads to the US, as RayzeBio runs into problems
Supply continues to cause headaches for radiopharmaceutical developers.
